IN2014DN01605A - - Google Patents
Info
- Publication number
- IN2014DN01605A IN2014DN01605A IN1605DEN2014A IN2014DN01605A IN 2014DN01605 A IN2014DN01605 A IN 2014DN01605A IN 1605DEN2014 A IN1605DEN2014 A IN 1605DEN2014A IN 2014DN01605 A IN2014DN01605 A IN 2014DN01605A
- Authority
- IN
- India
- Prior art keywords
- gene
- ret
- fusion
- cases
- mutation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G01N33/5752—
-
- G01N33/57557—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171256 | 2011-08-04 | ||
| PCT/JP2012/069799 WO2013018882A1 (ja) | 2011-08-04 | 2012-08-03 | Kif5b遺伝子とret遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01605A true IN2014DN01605A (da) | 2015-05-15 |
Family
ID=47629396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1605DEN2014 IN2014DN01605A (da) | 2011-08-04 | 2012-08-03 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9216172B2 (da) |
| EP (1) | EP2740742B1 (da) |
| JP (1) | JP6032616B2 (da) |
| KR (1) | KR20140047138A (da) |
| CN (1) | CN103764676A (da) |
| CA (1) | CA2848369A1 (da) |
| IN (1) | IN2014DN01605A (da) |
| WO (1) | WO2013018882A1 (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
| CN103119162B (zh) | 2010-09-02 | 2016-09-07 | 学校法人久留米大学 | 用于产生由单分子dna形成的环状dna的方法 |
| SG2014012728A (en) * | 2011-08-23 | 2014-06-27 | Foundation Medicine Inc | Novel kif5b-ret fusion molecules and uses thereof |
| US9416358B2 (en) | 2011-08-31 | 2016-08-16 | Kurume University | Method for exclusive selection of circularized DNA from monomolecular DNA in circularizing DNA molecules |
| US10023855B2 (en) * | 2011-10-31 | 2018-07-17 | Macrogen, Inc. | Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker |
| RU2648818C2 (ru) | 2012-09-25 | 2018-03-28 | Чугаи Сейяку Кабусики Кайся | Ингибитор ret |
| EP3470845B1 (en) * | 2013-03-15 | 2020-05-13 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
| WO2015025866A1 (ja) | 2013-08-20 | 2015-02-26 | 独立行政法人国立がん研究センター | 肺がんで見出された新規融合遺伝子 |
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| JP6816100B2 (ja) | 2015-07-16 | 2021-01-20 | アレイ バイオファーマ、インコーポレイテッド | RETキナーゼ阻害物質としての置換ピラゾロ[1,5−a]ピリジン化合物 |
| WO2017079140A1 (en) | 2015-11-02 | 2017-05-11 | Blueprint Medicines Corporation | Inhibitors of ret |
| AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018102455A1 (en) | 2016-12-01 | 2018-06-07 | Ignyta, Inc. | Methods for the treatment of cancer |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018213329A1 (en) | 2017-05-15 | 2018-11-22 | Blueprint Medicines Corporation | Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity |
| CA3073375A1 (en) * | 2017-08-21 | 2019-02-28 | Taiho Pharmaceutical Co., Ltd. | Fusion protein of dctn1 protein with ret protein |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| JP7422084B2 (ja) | 2018-04-03 | 2024-01-25 | ブループリント メディシンズ コーポレイション | Ret変化を有する癌の処置において使用するためのret阻害剤 |
| EP3833372A4 (en) | 2018-08-10 | 2022-06-08 | Blueprint Medicines Corporation | TREATMENT OF EGFR MUTANT CANCER |
| EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CN111154872A (zh) * | 2019-12-31 | 2020-05-15 | 浙江大学 | 用于检测肺癌驱动性基因突变的探针及试剂盒 |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CN111909987A (zh) * | 2020-07-31 | 2020-11-10 | 浙江科途医学科技有限公司 | 用于kif5b-ret融合基因检测的试剂组合物、试剂盒及检测系统 |
| CN113637709B (zh) * | 2021-08-14 | 2023-01-17 | 中国农业科学院兰州兽医研究所 | Kif5b基因作为靶点在抑制口蹄疫病毒复制中的应用 |
| JP2023177142A (ja) * | 2022-06-01 | 2023-12-13 | 国立研究開発法人国立がん研究センター | Retキナーゼ阻害剤によるがん治療の有効性を判定する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598052B2 (en) * | 2005-10-11 | 2009-10-06 | The Regents Of The University Of Michigan | Expression profile of thyroid cancer |
| EP1941909A4 (en) | 2005-10-24 | 2012-05-23 | Takeda Pharmaceutical | PREVENTIVE MEASURES / REMEDIES FOR CANCER |
| EP2089003A1 (en) | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| EP1920767A1 (en) | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| WO2010000012A1 (en) * | 2008-07-03 | 2010-01-07 | The University Of Sydney | Method for preventing transport of a neurotropic virus |
| US20130137111A1 (en) * | 2010-07-26 | 2013-05-30 | Astellas Pharma Inc. | Detection method of novel ret fusion |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
-
2012
- 2012-08-03 IN IN1605DEN2014 patent/IN2014DN01605A/en unknown
- 2012-08-03 JP JP2013526964A patent/JP6032616B2/ja active Active
- 2012-08-03 US US14/236,900 patent/US9216172B2/en active Active
- 2012-08-03 KR KR20147004610A patent/KR20140047138A/ko not_active Withdrawn
- 2012-08-03 CN CN201280038650.4A patent/CN103764676A/zh not_active Withdrawn
- 2012-08-03 EP EP12820601.8A patent/EP2740742B1/en active Active
- 2012-08-03 WO PCT/JP2012/069799 patent/WO2013018882A1/ja not_active Ceased
- 2012-08-03 CA CA 2848369 patent/CA2848369A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140221404A1 (en) | 2014-08-07 |
| KR20140047138A (ko) | 2014-04-21 |
| US9216172B2 (en) | 2015-12-22 |
| EP2740742A4 (en) | 2015-06-17 |
| EP2740742A1 (en) | 2014-06-11 |
| JPWO2013018882A1 (ja) | 2015-03-05 |
| WO2013018882A1 (ja) | 2013-02-07 |
| JP6032616B2 (ja) | 2016-11-30 |
| CN103764676A (zh) | 2014-04-30 |
| CA2848369A1 (en) | 2013-02-07 |
| EP2740742B1 (en) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN01605A (da) | ||
| EP4116293A3 (en) | Rho kinase inhibitors | |
| GB201103062D0 (en) | Method | |
| WO2016065349A3 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
| EA201792663A1 (ru) | Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr | |
| PH12015500832A1 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| PH12018500317A1 (en) | Salts of an lsd1 inhibitor | |
| MX2012009030A (es) | Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa. | |
| SG10201811175WA (en) | Method for treating cancer using a combination of chk1 and atr inhibitors | |
| NZ601606A (en) | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors | |
| MX2022015737A (es) | Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm). | |
| MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
| WO2013182912A3 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| IN2014DN06164A (da) | ||
| BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
| CA2864161A1 (en) | Inhibition of the glycine cleavage system for treatment of cancer | |
| EP3712264A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
| EA201792344A1 (ru) | Ген мужской стерильности пшеницы wms и его промотор специфичной для пыльника экспрессии и их применение | |
| MX2016013600A (es) | Método para tratar adenocarcinoma de pulmón. | |
| BR112014024487A2 (pt) | métodos para aumentar a eficácia da terapia baseada em cd37 | |
| MX371119B (es) | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. | |
| MY169029A (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
| WO2015048793A3 (en) | Nucleic acid biomarker and use thereof | |
| EA201301336A1 (ru) | Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии |